Concizumab (Alhemo) for Hemophilia A or B with Inhibitors
Concizumab (commercial name, Alhemo), a monoclonal antibody was approved bythe FDA on 20 December 2024 for prevention of bleeding episodes in...........
#Alhemo #Concizumab #FDA #HemophiaB #Hemophilia #HemophiliaA
SCIEU Team

https://www.scientificeuropean.co.uk/medicine/concizumab-alhemo-for-hemophilia-a-or-b-with-inhibitors/